Rigontec GmbH raises $5.3 mln in Series A

Rigontec GmbH said Tuesday it raised 4.8 million Euros (about US$5.3 mln) in a second closing of a series A round from Forbion Capital Partners and Sunstone Capital. Rigontec said total Series A funding was 14.25 million Euros (US$15.7 mln). Bonn, Germany-based Rigontech is a biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases.

North AmericaUSBriefs